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Inducible knockoutThe transcription factors required to initiate myogenesis in branchial arch- and somite-derived muscles are
known, but the comparable upstream factors required during extraocular muscle development have not
been identiﬁed. We show Pax7 is dispensable for extraocular muscle formation, whereas Pitx2 is cell-
autonomously required to prevent apoptosis of the extraocular muscle primordia. The survival requirement
for Pitx2 is stage-dependent and ends following stable activation of genes for the muscle regulatory factors
(e.g.Myf5,MyoD), which is reduced in the absence of Pitx2. Further, PITX2 binds and activates transcription
of the Myf5 and MyoD promoters, indicating these genes are direct targets. Collectively, these data
demonstrate that PITX2 is required at several steps in the development of extraocularmuscles, acting ﬁrst as
an anti-apoptotic factor in pre-myogenic mesoderm, and subsequently to activate the myogenic program in
these cells. Thus, Pitx2 is the ﬁrst demonstrated upstream activator of myogenesis in the extraocular
muscles.gy & Visual Science, University
Fax: +1 734 9367231.
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Throughout development, networks of transcription factors acti-
vate the step-wise progression of cell fate decision-making, enabling
phases of competence, speciﬁcation, and differentiation. Often, these
networks are re-used spatially and temporally during development
with different variations such as substituting paralogs, swapping
repressors for activators, or utilizing a different transcription factor at
the top of a transcriptional cascade. In skeletal muscle development,
the common cassette of muscle regulatory factors (MRFs), the
transcription factors Myf5 (GeneID: 17877), Mrf4 (17878), MyoD
(17927), and Myogenin (17928), induces speciﬁcation and differenti-
ation in all muscle progenitors, but upstream activator(s) of MRFs
differ between the somitic, branchial arch, and extraocular muscles.
Therefore, extraocular muscles provide an excellent opportunity to
study a common transcriptional network that has evolved to generate
specialized functions.
Extraocular muscles (EOMs) have evolved properties that enhance
binocular vision, such as extreme speed, contractile precision, and
fatigue resistance,whichmake themunique among the skeletalmuscles
(reviewed in Spencer and Porter, 2006). EOMs also have unique geneexpression proﬁles relative to other skeletal muscles, which include the
presence of embryonic and cardiac muscle proteins as well as higher
levels of enzymes that lead to improved calcium homeostasis and
reduced oxidative stress (Porter et al., 2006). These unique properties
make the EOMs resistant to many forms of muscular dystrophy (Porter
et al., 2003).
Given the unique properties of extraocular muscles, it is not
surprising that their development is unique as well. The differences
in the early steps of trunk versus craniofacial myogenesis have been
well documented; the trunk muscles develop from somites, whereas
the craniofacial muscles develop from unsegmented prechordal and
paraxial mesoderm (reviewed in Noden and Francis-West, 2006).
The response of myogenic cells to extracellular signals also differs
between the trunk and head (Tzahor et al., 2003). Pax3 (18505),
which activates MRF expression in the somites, is not expressed in
the developing craniofacial muscles (Bajard et al., 2006; Horst et al.,
2006). However, the development of the extraocular muscles also
differs from craniofacial muscles formed in the branchial arches.
Tbx1 (21380), Musculin (MyoR, 17681), and Tcf21 (Capsulin, 21412)
are upstream activators of MRFs in the branchial arches, but
individually they are not required for EOM formation (Kelly et al.,
2004; Lu et al., 2002). Analogous transcriptional activators of the
MRF myogenic cascade have not been identiﬁed in the extraocular
muscles.
In contrast, the MRF transcriptional cassette is required for
myogenesis in all muscle lineages, and a recent analysis by
Sambasivan et al. identiﬁed the speciﬁc functions of the MRFs in
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functions that are absolutely required for EOM formation. Mice
lacking either Myf5 or Mrf4 have largely normal EOMs, whereas mice
with null mutations in both genes lack differentiated EOMs. The
authors attribute this loss to the failure to activate MyoD, which
rescues muscle speciﬁcation in the absence of Myf5/Mrf4 in the
somites, and the subsequent apoptosis of the EOM primordia
beginning at e11.0, suggesting that the MRFs function as survival
factors. A small number of MYOD/MYOGENIN positive cells remain in
theMyf5/Mrf4 double mutant animals, suggesting other pathways can
activate MyoD, although this is apparently insufﬁcient to generate
differentiated muscle (Sambasivan et al., 2009). These data clarify the
roles of the MRFs of the EOMs, but leave the identity of the upstream
activators unresolved.
Two transcription factors, Pax7 (18509) and Pitx2 (18741), have
been proposed to be upstream activators of the MRF cascade in the
EOM primordia (Diehl et al., 2006; Mootoosamy and Dietrich, 2002;
Shih et al., 2007a). Pax7 is expressed in the developing cranial muscles
and it can activate MRF expression in development and regeneration
(Kuang et al., 2006; Mootoosamy and Dietrich, 2002; Relaix et al.,
2006; 2005). However, the potential functions of Pax7 in EOM
myogenesis have never been examined in detail, although recent
experiments suggest it may not be required for EOM development
(Relaix et al., 2004; Sambasivan et al., 2009). In contrast, the
homeodomain transcription factor Pitx2 is the only single gene
shown to be required for extraocular muscle development. Mice
lacking Pitx2 function have no extraocular muscles and their
formation is dependent on Pitx2 gene dose (Diehl et al., 2006; Gage
et al., 1999; Kitamura et al., 1999). Hypomorphic Pitx2 mutants with
approximately 20% of normal gene dose also lack extraocular muscles.
Heterozygous Pitx2 embryos have no oblique muscles, smaller rectus
muscles, and expression of the MRFs Myf5, MyoD, and Myogenin is
reduced to 10–20% of wildtype levels (Diehl et al., 2006). In adult
EOMs, Pitx2 continues to be expressed in satellite cells. Post-natal
knockdown of Pitx2 in the extraocular muscles showed a dramatic loss
of MRF expression levels, suggesting Pitx2 may be important for
satellite cell function (Zhou et al., 2009). Overexpression of a Pitx2-
engrailed dominant repressor construct reduces MRF expression in
chick somites, suggesting regulation of the MRFs by PITX2 may be
direct (Abu-Elmagd et al., 2010). The expression of Pitx2 is unaffected
in the Myf5;Mrf4 double mutants, providing further evidence that
Pitx2 functions upstream of the MRFs (Sambasivan et al., 2009).
In addition to the mesodermal cells that are fated to form
myoﬁbers, the developing EOMs also receive contributions from the
ocular neural crest, which produce tendons and connective fascia
(Gage et al., 2005). Recent work has highlighted the complex
interactions between neural crest and mesodermal cells in craniofa-
cial development (Evans and Noden, 2006; Grenier et al., 2009; Rinon
et al., 2007). Although Pitx2 is expressed in both populations, its
function is not required in the neural crest for initiation of extraocular
myogenesis (Evans and Gage, 2005). This suggests Pitx2 is required in
the mesoderm lineage for EOM formation, where it may activate MRF
expression.
Here we show that Pax7 does not function in EOM speciﬁcation,
based on the timing of its expression relative to the MRFs and the
presence of EOMs in Pax7 mutant mice. We use lineage-speciﬁc
knockout mice to demonstrate that EOM development requires Pitx2
expression in the pre-myogenic mesoderm, and we show that EOM
primordia lacking Pitx2 undergo apoptosis prior to MRF activation.
Delaying the ablation of Pitx2 permits EOM precursor survival,
however Pitx2 continues to be required to prevent apoptosis at later
stages as well. We found MRF levels are reduced in the absence of
Pitx2 and PITX2 can bind and activate the promoters of two key MRFs,
Myf5 and MyoD. These results indicate PITX2 plays key roles in both
the survival and speciﬁcation of extraocular muscles, in part through
activation of the MRFs.Materials and methods
Mouse husbandry
All experiments were conducted in accordance with the NIH
Guidelines for the Care and Use of Experimental Animals and all
procedures involvingmicewere approvedby theUniversity ofMichigan
Committee on Use and Care of Animals. Mice were mated to generate
timed pregnancies. The relevant crosses include: T-Cre; Pitx2+/null×
Pitx2ﬂox/+; R26R/R26R, UBC-CreERT2; Pitx2+/null×Pitx2ﬂox/ﬂox; R26R/R26R,
Pitx2+/null×Pitx2+/null, Pax7LacZ/+×Pax7LacZ/+. If indicated, a single
intraperitoneal injection of tamoxifen (Sigma) suspended in corn oil
at a dose of 100 µg/g body weight was administered to the pregnant
dam at noon on the day noted. The resulting embryos were genotyped
forCre or Pitx2using PCR-basedmethods as per the Jackson Laboratories
(Suh et al., 2002), and processed for histology as previously described
(Evans and Gage, 2005).
Immunostaining and in situ hybridization
Parafﬁn sections were immunostained as previously described
(Evans and Gage, 2005). Primary antibodies against PITX2 (a gift from
T. Hjalt), PITX1 (a gift from J. Drouin), b-galactosidase (Eppendorf 5′),
developmental myosin heavy chain (Vector), Ki67 (Dako Cytomation),
MYOD (Abcam), Myogenin (Santa Cruz), MYF5 (Santa Cruz), and PAX7
(developed by A. Kawakami and obtained from NICHD/Developmental
Studies Hybridoma Bank) were used. Digoxigenin-labeled riboprobes
against Pitx2 were generated and used to stain parafﬁn sections as
previously described (Cushman et al., 2001; Martin et al., 2002).
Cell death analysis
Three to four non-adjacent sections from three wildtype and four
heterozygous e10.5 embryos were stained for Terminal dUTP nick end
labeling (TUNEL), PITX2 immunostaining, and DAPI using an In situ
Cell Death Detection kit (Roche) per manufacturer protocol, followed
by a standard immunostaining protocol with the hydrogen peroxide
blocking step omitted. The number of TUNEL/PITX2/DAPI-labeled
EOM primordia was divided by the number of PITX2/DAPI-labeled
cells for the percentage of EOM primordia undergoing cell death. Nine
total wildtype observations were statistically compared to 15 total
Pitx2 heterozygote observations using a Student's t-test.
Quantitative RT-PCR
Quantitation ofMRF expression levels was performed using TaqMan
Gene Expression Assays and Master Mix (Applied Biosystems) as
previously described (Gage et al., 2008). cDNA was generated as
previously described from the heads of e11.5 mouse embryos of the
noted genotypes, which were microdissected to remove the branchial
arches and portions of the brain, leaving the eyes and the surrounding
tissues. Relative fold changes compared to controls and standard error
were calculated from 3–4 samples of each genotype using the 2−ΔΔCt
method and normalized to Hprt.
Chromatin immunoprecipitation (ChIP)
C2C12 and mEOM (Porter et al., 2006) cells were grown to 80%
conﬂuency and subjected to ChIP assays as previously described
(Gummow et al., 2006). For immunoprecipitation, two polyclonal
antibodies speciﬁc for PITX2 were used (Santa Cruz, goat C-16 and
rabbit H-80), as well as control antibodies as previously described
(Gage et al., 2008). Puriﬁed DNA fragments were analyzed by PCR
using the primers described in Table S1.
Fig. 1. Mesoderm-speciﬁc knockout of Pitx2 results in the absence of extraocular
muscles. Sagittal sections behind the globe of the eye allow for visualization of all seven
extraocular muscles at later developmental timepoints, such as e14.5 (A). Immunohis-
tochemistry for developmental myosin heavy chain (dMHC) shows T-Cre+; Pitx2ﬂox/null
mutant embryos have little (C) to no (D) differentiated extraocular muscle at e14.5, as
compared to either T-Cre+; Pitx2+/+ (A) or T-Cre+; Pitx2+/null (B) controls. SO, superior
oblique; SR, superior rectus; MR, medial rectus; RB, retractor bulbus; LR, lateral rectus;
IR, inferior rectus; IO, inferior oblique.
397A.L. Zacharias et al. / Developmental Biology 349 (2011) 395–405Luciferase assays
The PITX2wildtype and T30Pmutant expression constructs were a
gift from Michael Walter and have been previously described
(Kozlowski and Walter, 2000). A 317 bp MyoD minimal promoter
fragment contains 124 bp upstream of the transcriptional start site
(TSS) and the 5′UTR cloned into in the pFL-basic luciferase reporter
vector, and a similar plasmid containing 410 bp of the Myf5 minimal
promoter includes 202 bp upstream of the TSS and the 5′UTR.
Luciferase assays using these reporter vectors were carried out as
previously described (Gage et al., 2008).
Results
Expression of transcription factors during myogenesis
To evaluate the proposed factors upstream of the MRF myogenic
cascade, we examined the presence of PITX2 and PAX7 protein during
primary myogenesis in wildtype EOMs. PITX2 is expressed in the
unspeciﬁed pre-myogenic mesoderm fated to form EOMs (referred to
here as EOM primordia) as early as e8.5 (Shih et al., 2007b), whereas
expression of MYF5, the earliest MRF, is present in a small number of
cells at e10.5 and expands by e11.5 (Figs. S1E, F). PAX7 and the other
MRFs, MYOD, and MYOGENIN, are not observed until e11.5 (Fig. S1).
The expression of PITX2 is more widespread than the MRFs,
throughout the EOM primordia at both e11.5 and e12.5, suggesting
not all EOM precursors have activated MRF expression by e12.5 (Figs.
S1U–X). Since the MRFs are functional markers of muscle speciﬁca-
tion, this indicates EOM cells are speciﬁed during a period of several
days, beginning at e10.5 and extending beyond e12.5. Persistent
expression of PITX2 and the MRFs in a large proportion of EOM cells
remains as late as e16.5 (Fig. S1). Overall, these data indicate Pitx2 is
temporally upstream of the MRFs, which is consistent with a potential
role in activating them.
In contrast, the presence of MRF expression prior to the activation
of Pax7 indicates Pax7 is unlikely to be an upstream regulator of the
MRFs. We conﬁrmed this by examining Pax7LacZ/LacZ knockout mice
(MGI:3047633), which have normal expression of the MRFs and
PITX2 in the extraocular muscle precursors at e12.0 (Fig. S2). Pax7
mutant EOMs differentiate normally by e14.5 as indicated by the
presence of myosin heavy chain (Figs. S2I, J), demonstrating Pax7 is
not required for the embryonic speciﬁcation and differentiation of the
extraocular muscles and it is not the upstream activator of the MRFs
during early development. We therefore focused our efforts on
determining the functions of Pitx2 during EOM development and
evaluating its potential to activate the MRFs.
Mesoderm-speciﬁc Pitx2 knockout mice lack EOMs
It was previously shown that mice with neural crest-speciﬁc
knockout of Pitx2 recapitulate most aspects of the Pitx2 global
knockout ocular phenotype, except that initiation of myogenesis in
the extraocular muscles is unaffected (Evans and Gage, 2005). We
hypothesized that a primary function of Pitx2 in the mesodermal
lineage during eye development is to direct extraocular muscle
formation. To test this, mesoderm-speciﬁc Pitx2 knockout (Pitx2-mko)
micewere created using the T-Cre transgene (MGI:3605847), which is
broadly expressed in mesoderm at gastrulation, with a conditional
Pitx2ﬂox allele (MGI:1857844) (Perantoni et al., 2005). Based on Cre-
mediated activation of a LacZ reporter, mesoderm cells are found
ventral to the optic vesicle at e9.5 (Fig. S3). By e11.5, the mesoderm
condenses into a wedge shape, which separates into individual
developing EOMs beginning at e12.5 (Fig. S3).
Since Pitx2+/null embryos have a reduced EOM phenotype, both
T-Cre+; Pitx2+/null and T-Cre+; Pitx2+/+ embryos were used as
controls for the T-Cre; Pitx2ﬂox/null mutants. Pitx2-mko mutant embryoshave extremely reduced or completely absent extraocular muscles
(Fig. 1). The Pitx2-mko embryos also have open eyelids at e16.5,
occasional retinal lamination defects, and failure of body wall closure
similar to the global Pitx2 knockout (Zacharias et al., in preparation;
Gage et al., 1999). The absence of EOMs in the Pitx2-mko mice
suggests that loss of Pitx2 causes a cell-autonomous defect in the
mesoderm-derived myoblasts that form the EOMs.
Pitx2 is required for EOM survival in a dose-dependent manner
To determine the fates adopted by EOM precursors in the absence
of functional Pitx2, we examined expression of the mutant Pitx2
mRNA produced by the Pitx2null allele. This mutant transcript is stable
because it can be identiﬁed by a Pitx2 probe targeting the 3′UTR.
However, any protein produced by the mutant mRNA is either non-
functional or degraded, because the homozygous Pitx2null/null mice
phenocopy other Pitx2 knockout mice (Gage et al., 1999; Kitamura
et al., 1999; Lin et al., 1999; Lu et al., 1999). In the wildtype and
heterozygous embryos, expression of Pitx2mRNA is observed in both
the neural crest cells that surround the optic cup and the
mesodermal cells that lie adjacent to the optic stalk (Figs. 2A, B).
Although robust Pitx2mRNA expression is seen in the neural crest at
e10.5 in Pitx2null/null global knockout (Pitx2-gko) embryos, little to no
expression is seen in the location where mesoderm cells fated to
form EOMs are normally present (Fig. 2C, arrow). Therefore, the EOM
primordia are absent in Pitx2-gko mice.
To examine the possibility the EOM primordia were lost to cell
death, TUNEL staining was performed. In Pitx2null/null embryos,
widespread cell death is observed in the region where Pitx2-
expressing EOM primordia are normally found (Fig. 2F). Cell death
was also increased in Pitx2+/null EOM primordia (Fig. 2E), and the
number of PITX2-positive cells co-labeled with TUNEL was signiﬁ-
cantly greater than wildtype littermates (pb0.007) (Fig. 2G). No
difference in apoptosis was observed at e9.5 or e11.5 (data not
shown), indicating that in EOM primordia lacking Pitx2, coordinated
apoptosis occurs during a narrowly deﬁned period, just prior to e10.5.
Because Pitx2 has been implicated in cell proliferation, and
disruptions in cell cycle progression often lead to apoptosis (Charles
et al., 2005; Hipfner and Cohen, 2004; Kioussi et al., 2002), cell
proliferation was examined in the EOM primordia at e9.5, prior to the
Fig. 2. Loss of Pitx2 causes apoptosis in EOM primordia but does not affect cell proliferation. In both control (A) and heterozygote (B) e10.5 eyes, Pitx2 mRNA is expressed in the
neural crest cells which surround the optic cup (arrowheads) and the mesoderm cells which lie just adjacent to the optic stalk (arrow). In Pitx2null/null mutant eyes (C), expression
surrounding the optic cup remains (arrowheads), but expression in the mesoderm is strikingly absent (arrow), indicating the absence of the EOM primordia. TUNEL staining shows
an increase in the percentage of PITX2-positive cells also labeled with TUNEL in the Pitx2 heterozygote (E) EOM primordia as compared to the control (D), which is statistically
signiﬁcant (G). In Pitx2null/null mutant eyes (F), there is a massive increase in TUNEL labeled cells in the region where the EOM primordia are normally found, demonstrating these
cells are lost to apoptosis. Very few PITX2-positive EOM primordia cells (dotted line) also labeled with the proliferation marker Ki67 in wildtype embryos (H, J), and an
approximately equal numbers of cells labeled with Ki67 in Pitx2 mutant EOM primordia (dotted lines) at both e10.5 (I) and e9.5 (K).
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proliferating in the wildtype EOM primordia, but no differences were
noted between mutant and wildtype embryos (Figs. 2H–K). Thus,
defects in proliferation are unlikely to be the mechanism underlying
the dramatic increase in apoptosis seen in the EOMprimordia of Pitx2-
gko embryos.
Pitx2 is required for EOM precursor speciﬁcation and survival
Previous data suggested Pitx2 has a role in EOM speciﬁcation as
well as survival of the EOM primordia (Diehl et al., 2006). However,
Pitx2null/null EOM primordia undergo apoptosis before they express
any MRF markers of muscle speciﬁcation (Fig. S1). To determine if
Pitx2 has functions in later EOM development, we generated mutants
inwhich the loss of Pitx2 function is delayed until after the initial stage
when it is required for cell survival. This was accomplished by creating
a temporal knockout of Pitx2 using a ubiquitously expressed CreERT2
(see Fig. S4, MGI:3707333)(Ruzankina et al., 2007). We bred UBC-
CreERT2+; Pitx2+/null males to Pitx2ﬂox/ﬂox females and injected the
pregnant dams with the appropriate dose of tamoxifen at e10.5
(abbreviated TMX10, etc.). A nearly complete loss of PITX2 protein
expression was observed 24 h post-injection (Figs. 3B, C). TamoxifenFig. 3.Delaying Pitx2 deletion until e10.5 can temporarily rescue EOM primordia survival. UB
PITX2 protein expression 24 h later at e11.5. While control embryos (A) had normal PITX2 e
that expressed PITX2 at high levels (C, arrows), indicating the Cre-mediated excision of the P
(arrow) are still present in e11.5 UBC-CreERT2+; Pitx2ﬂox/null embryos treated with tamoxi
increased TUNEL staining (H, I) at e11.5 as compared to controls (G). At e12.5, Pitx2 in situ h
controls (J–L) and have increased TUNEL staining (M–O). By e14.5, TMX10 mutants have no
mutants do not show increased TUNEL staining, but instead show a reduced number of cell
oculo-sphenoid bone of the skull (B). Red blood cells also inﬁltrate the empty spaces (R, Utreatment at other timepoints resulted in equally efﬁcient ablation of
PITX2 (data not shown). For all temporal knockout experiments UBC-
CreERT2+; Pitx2ﬂox/null mutants were compared to Pitx2ﬂox/null hetero-
zygote littermates, because Pitx2+/null mice have an EOM phenotype.
To determine if survival of the EOM precursors could be rescued
by early Pitx2 expression and to evaluate the role of Pitx2 in activating
muscle speciﬁcation at e11.5 and beyond, timed pregnant damswere
injected with tamoxifen at e10.5 (TMX10). Embryos were harvested
at e11.5, e12.5, e13.5 and e14.5 and analyzed for the presence of EOM
primordia and expression of myogenic markers. To determine if
expression of Pitx2 prior to e10.5 could rescue the EOM primordia
from apoptosis, we examined Pitx2 mRNA to identify the primordia
and TUNEL labeling to identify apoptotic cells. In eight of eight eyes
from four mutants examined at e11.5, the EOM primordia could be
identiﬁed by Pitx2 mRNA expression, indicating early expression of
Pitx2 extended cell survival (Figs. 3E, F arrows). Unlike the Pitx2-gko,
apoptosis in the EOM primordia was not strikingly affected, but the
percentage of cells labeled with TUNEL is reproducibly increased in
the mutant embryos as compared to the controls (Figs. 3G–I). By
e12.5, the EOM primordia of TMX10 mutant embryos were
noticeably reduced in size compared to the heterozygous controls
(Figs. 3J–L). Apoptosis was also increased in mutant primordiaC-Cre+; Pitx2ﬂox/nullmutant embryos treated with tamoxifen at e10.5 were examined for
xpression, mutant embryos either had no PITX2 expression (B), or a few remaining cells
itx2ﬂox allele had failed. Pitx2mRNA expression (D–F) indicates the EOM primordia cells
fen at e10.5 (TMX10 mutants). However, the TMX10 mutant EOM primordia display
ybridization shows that the TMX10 mutant EOM primordia (arrows) are smaller than
EOM primordia cells, based on the expression of Pitx2 mRNA (P–R). The e14.5 TMX10
s based on DAPI staining (S–U), causing the optic nerve (ON) to be shifted closer to the
, arrowheads).
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condensations, but a few (2/7) had small EOM condensations
expressing Pitx2 mRNA (data not shown). Apoptosis was increasedin the mesenchyme of e13.5 TMX10 mutant eyes compared to the
heterozygote controls (data not shown). By e14.5, there is no
expression of Pitx2 mRNA, indicating that the EOM precursors are
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Table 1
Summary of phenotypes in TMX10 mutant embryos.
e11.5 e12.5 e13.5 e14.5
EOM primordia present 8/8 8/8 reduced 2/7 0/8
MRF+ cell present 8/8 8/8 2/7 0/8
Regions lack MYF5 2/8 1/8 1/2 –
Regions lack MYOD/MYOG 8/8 1/8 1/2 –
TUNEL increased 8/8 8/8 7/7 7/8 reduced cellularity
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seen in e14.5 TMX10 mutants (Figs. 3S–U), presumably because the
dead cells were already cleared. There is a noticeable decrease in the
number of cells surrounding the optic nerve, suggesting prior cell
death in this region (Figs. 3S–U). Together, these data demonstrate
that even after e10.5, EOM precursors require Pitx2 for survival.
Deletion of Pitx2 at e10.5 provided temporary rescue of the
apoptosis seen in Pitx2-gko EOM primordia, which enabled us to
examine the role of Pitx2 in MRF activation. At e11.5, 24 h after Pitx2
ablation, some cells still expressed MYF5, MYOD and MYOGENIN, but
the number of EOM precursors expressing no MRFs was signiﬁcantly
increased (Figs. 4A–I, S5). MYF5 expression by immunohistochemis-
try was not spatially restricted, but the percentage of EOM primordia
cells (as deﬁned by the expression of Pitx2mRNA) labeled with MYF5
protein decreased signiﬁcantly from 46% on average to just 15% (Fig.
S5). All EOM primordia had regions lacking MYOD and MYOGENIN
protein expression, with two of eight showing complete loss of
expression. In primordia that retained expression, the percentage of
cells expressing MYOD and MYOGENIN decreased from 10% and 7% to
3% and 4% respectively, representing statistically signiﬁcant decreases
(Fig. S5). The changes in percent expression indicate that the decrease
in MRF expression cannot be explained merely by reduction in
primordia size. To further quantitate the effect of the loss of Pitx2 on
MRF expression, we used qRT-PCR to measure transcript levels in
e11.5 TMX10 dissected embryos. We found Myf5, Mrf4, MyoD and
Myogenin were signiﬁcantly reduced in mutants relative to both
wildtype and heterozygous embryos, with MyoD being the most
severely affected (Fig. 4J). At e12.5, the MRF proteins MYF5, MYOD,
and MYOGENIN were expressed throughout the smaller TMX10
mutant EOM primordia, although the overall number of MRF-positive
cells was decreased relative to the control (Figs. 4K–P, data not
shown). In the two e13.5 TMX10 embryos that had EOM primordia
(2/7), both had a few cells that expressedMRFs, although the number
was substantially reduced relative to controls (Figs. 4Q, R). The e13.5
and e14.5 TMX embryos that lacked EOM primordia also had no
expression of MRFs or markers of muscle differentiation, indicating
the complete absence of extraocular muscle (Fig. 4S, Table 1, data not
shown).
To identify the window during which Pitx2 is required for the
survival of EOM primordia, we delayed the tamoxifen injections until
e11.5, e12.5 or e14.5. Treatment with tamoxifen at e11.5 or e12.5
resulted in partial restoration of EOM development in mutants, as
evidenced by the presence of EOM primordia with substantially more
widespread MRF expression than was observed in TMX10 mutants
(compare Figs. 5A–I vs. Fig. 4). However, apoptosis in TMX11 andFig. 4. Loss of Pitx2 at e10.5 reduces MRF expression in the EOM primordia. The loss of Pitx2 in
(dotted line, based on Pitx2mRNA expression in Fig. 4) labeled with MYOD (B, C) and MYOG
TMX10mutant EOMs (G–I). Quantitative RT-PCR on wildtype, heterozygote control and mut
(J). The relative expression levels+/−SEM are normalized to the heterozygote controls to s
and Myog are reduced at a greater level of statistical signiﬁcance than Mrf4 (J). At e12.5, the
shown) throughout their smaller EOM primordia. At e13.5, most TMX10mutants have no EO
and MYOD (R), although the number of labeled cells is dramatically reduced as compared to
some panels (A–F, K–M).TMX12 mutant EOM primordia remains higher than in control EOMs
(Figs. 5D–I). Differentiated muscles are present at e16.5 in TMX12
mutants, based on the expression of desmin (Figs. 5J–L), indicating
Pitx2 function may not be required for EOM differentiation. However,
the requirement for Pitx2 to ensure cell survival is not complete by
e12.5 as evidenced by the increased apoptosis (Figs. 5G–I) and
reduced EOM size in TMX12 mutants as compared to control
littermates (Figs. 5J–L). Tamoxifen treatment at e14.5 results in
normal EOM development, as judged by MRF expression, absence of
apoptosis, and overall muscle size (data not shown). This indicates the
developmental period during which Pitx2 is required for EOM
precursor survival ends between approximately e12.5–14.5.
Pitx2 can bind and activate MRF promoters
The initial reduction of the MRFs at e11.5 in response to the loss of
PITX2, together with data from previous reports, lead us to
hypothesize that PITX2 may directly activate the expression of the
MRFs (Abu-Elmagd et al., 2010; Diehl et al., 2006; Zhou et al., 2009).
We focused on the ability of PITX2 to activateMyf5 andMyoD, because
MyoD was most strongly reduced and Myf5 is more dramatically
affected by the loss of Pitx2 than Mrf4 (Fig. 4J), and it is expressed at
sixteen fold higher levels than Mrf4 (data not shown), suggesting
Myf5 may be the dominant early MRF in the EOMs. We did not
examine the ability of Pitx2 to activate the expression of Myogenin,
because it is downstream of bothMyoD andMyf5 (Cheng et al., 1995;
Yee and Rigby, 1993). We focused on three elements previously
shown to drive LacZ expression in the correct time and place during
EOM development, the Myf5 promoter, the MyoD promoter, and the
MyoD 258 bp enhancer (Goldhamer et al., 1995; 1992; Patapoutian
et al., 1993). These regions were examined, and predicted bicoid-like
PITX2 binding sites were identiﬁed in each (Fig. 6A). Chromatin
immunoprecipitation (ChIP) was used to determine if PITX2 physi-
cally associates with these regions in two muscle precursor lines:
C2C12 cells, which are limb derived, and a mouse EOM (mEOM)
primary cell line (Porter et al., 2006). Both cell lines express PITX2
endogenously (data not shown). ChIP with an antibody against PITX2
shows enrichment for the Myf5 proximal promoter as compared to
control antibodies, but no enrichment is observed for the negative
control region (Fig. 6B). ChIP also indicates that PITX2 binds theMyoD
proximal promoter, but not the 258 bp MyoD enhancer or negative
control (Fig. 6B). Similar results were obtained in both limb muscle
and EOM precursors. These results conﬁrm that PITX2 physically
interacts with the promoters of MRF genes.
To examine if PITX2 binding to the MRF promoters is functionally
signiﬁcant, we tested the ability of the Myf5 and MyoD proximal
promoters to drive luciferase expression in response to PITX2 in
C2C12 cells. Both the Myf5 andMyoD proximal promoters respond to
increasing doses of PITX2-expression vector, but not to transcription-
ally-deﬁcient mutations of PITX2 (Fig. 6C and data not shown)
(Kozlowski and Walter, 2000). These data indicate PITX2 can activate
the Myf5 and MyoD promoters in vitro.
Discussion
The transcription factors upstream of trunk and branchial arch
myogenesis have been deﬁned, but the factors upstream ofTMX10mutants results in a signiﬁcantly reduced number of cells in the EOM primordia
(E, F) as compared to controls (A, D). MYF5 expression is not as dramatically affected in
ant e11.5 TMX10 embryos demonstrates the MRF mRNA levels are signiﬁcantly reduced
how the differences between mutant, heterozygote and wildtype. Levels ofMyf5,Myod,
TMX10 mutants have expression of MYOD (K–M), MYOG (N–P), and MYF5 (data not
M primordia cells and lackMRF expression (S), but a few have some expression of MYF5
control EOMs (Q, arrows). Autoﬂuorescent red blood cells appear as yellow or green in
Fig. 5. Further delaying Pitx2 deletion restores MRF expression but results in reduced EOM size. EOMs of e14.5 TMX11 mutants retain expression of MYF5 and MYOD (A–C), as well as
MYOG (D–F). However, an increased number ofmutant EOMprecursor cells, their locationmarked by the expression ofMYOG, labelwith TUNEL (arrows) in both e14.5 TMX11 (D–F) and
TMX12(G–I) embryos, indicating an increase in apoptosis in theabsence ofPitx2. Desminexpression isunaffected ine16.5 TMX12mutant EOMs(K, L), but they are smaller than the control
EOMs (J). Autoﬂuorescent red blood cells appear yellow or orange in panels J–L.
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Here we show Pax7 is dispensable for extraocular muscle formation,
whereas Pitx2 plays multiple roles in primary extraocular myogenesis,
controlling both EOM primordia survival, by an as yet unknown
mechanism, as well as muscle speciﬁcation by directly activating
expression of MRFs.
Pitx2 is required for EOM survival
We show Pitx2 is cell-autonomously required in EOM primordia
cells for their survival prior to e10.5. Pitx2 is required in a dose-
dependent manner to prevent apoptosis in the mesoderm-derived
muscle precursors, which explains why EOM size correlates with Pitx2
dose, as previously reported (Diehl et al., 2006). The absence of Pitx2
or removal of Pitx2 function at e9.5 results in the apoptosis of the EOM
primordia by e10.5, prior to activation of MRFs (Fig. 2 and data not
shown). This is earlier than the apoptosis reported in EOM precursors
lackingMyf5 andMrf4. In these embryos, apoptosis is ﬁrst observed at
e11.0, and a signiﬁcant number of Myf5nlacZ positive EOM precursors
remain at e12.5, indicating that the death of the EOM primordia
occurs gradually (Sambasivan et al., 2009). Thus, there is an earlier,
more absolute requirement for Pitx2 in EOM survival than there is for
the MRFs.Stable expression of the MRFs and continued survival are dependent on
Pitx2
Use of an inducible Cre-Lox system to delay deletion of Pitx2 until
e10.5 revealed that Pitx2 is required for full activation of theMRFs. Our
data suggest the MRF-negative cells observed at e11.5 are preferen-
tially lost as a result of failing to activate or maintain the myogenic
program. However, activation of theMRFs is apparently insufﬁcient to
prevent apoptosis in the absence of Pitx2. The progressive reduction in
the size of the EOM precursor population in TMX10mutants indicates
that cells are progressively lost to apoptosis, until all of the EOM
precursors are gone. Thus, even EOM precursors that express MRFs
are unable to survive in the absence of Pitx2. Interestingly, Pitx2 is
similarly unable to prevent apoptosis in Myf5;Mrf4 double mutant
EOM primordia (Sambasivan et al., 2009). Therefore, expression of
Pitx2 and theMRFsmust both be required for EOM primordia survival.
In contrast to the effects of deletion of Pitx2 at e10.5, post-natal
deletion of Pitx2 does not appear to affect survival of the extraocular
muscles, suggesting its requirement is transient (Zhou et al., 2009).
Here we used temporal deletion to demonstrate that Pitx2 function
beyond e10.5 enables EOM development to reach a point after which
the survival requirement for Pitx2 is greatly diminished. Further, they
suggest Pitx2 is not required for MRF expression once it has been
Fig. 6. PITX2 binds and activates the Myf5 and Myod1 promoters. Diagrams indicating
the previously described Myf5 and Myod1 promoters (A, not to scale) show the
transcriptional start site (arrows), the predicted PITX2 binding sites (*), and the
location of the primers used for ChIP (N b). The regions in gray correspond to the
minimal promoters used to drive luciferase expression. Chromatin immunoprecipita-
tion (B), shows PITX2 binds to the Myf5 and Myod1 promoters more strongly than
control antibodies (serum, IgG control) in both C2C12 limb muscle precursor cells and
mEOM primary cells. The Myod1 258 bp enhancer and negative control regions 10 kb
away from the promoters are not bound. The binding of a Pol II antibody to EF-1 is
shown as a positive control. The minimal Myf5 and Myod1 promoters respond
positively to increasing doses of PITX2 expression vector in luciferase reporter
experiments (C). Neither promoter responds to the transcriptionally dead T30P
mutation in PITX2, or to other transcriptionally compromised mutations (data not
shown).
Fig. 7. Model for Pitx2 functions in EOM development. A timeline (A) shows how the
Pitx2 requirement for survival in EOM primordia both precedes and overlaps with the
activation of MRF expression. Differentiation markers appear during the same time
frame that the requirement of Pitx2 for EOM survival ends. A three-step model for Pitx2
function in EOM development (B) shows that PITX2 is initially required for EOM
primordia survival (1), and is later required for MRF activation (2) and subsequently
the MRFs are also required for EOM survival (3). A model for the functions of PITX2 in
MRF activation in the EOMs (C, adapted from the model proposed by Sambasivan et al.)
shows that Pitx2 directly activates the expression of Myf5 and possibly Mrf4, which
regulateMyod, a gene that is also directly activated by Pitx2.Myod then activatesMyog,
which induces differentiation, a process in which Myod and Mrf4 may also play a role,
based on the development of other skeletal muscles.
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of EOMs. However, Pitx2 continues to be required for cell survival in at
least a subset of the EOM primordia. We hypothesize that this subset
represents unspeciﬁed EOM primordia cells that have not yet
activated MRF expression, which we observed at both e11.5 and
e12.5 (Fig. S1). Without Pitx2, these unspeciﬁed cells are unable to
activate MRF expression, and without either of these critical anti-
apoptotic factors, they undergo apoptosis. Data from late temporal
knockouts indicates that the requirement for Pitx2 ends by e14.5.
Therefore, the period in which Pitx2 is required for EOM precursor
survival and speciﬁcation begins at e9.5 and lasts until e12.5–e14.5, an
endpoint which overlaps with the end of MRF activation and the
initiation of EOM differentiation (Fig. 7A). An investigation of the role
for Pitx2 in secondary ﬁber formation in the time window betweenour studies and the post-natal studies of Zhou et al. remains to be
done.
Based on our results, we propose a three-step model for the
functions of Pitx2 and the MRFs in EOM speciﬁcation and survival
(Fig. 7B). First, Pitx2 is required for the survival of EOM primordia,
prior to the activation of the myogenic program. Second, Pitx2 is
required to specify the EOM primordia as muscle by activating MRF
expression. Finally, MRFs are required, but not sufﬁcient, to ensure
EOM precursor survival. Thus, Pitx2 has dual functions in EOM
primordia survival. It is required for a survival checkpoint at e9.5 and
Pitx2 continues to be required to prevent apoptosis until the EOM
primordia are fully speciﬁed by robustly activating MRFs. Once all
EOM precursors are speciﬁed and expressing MRFs at e14.5 and
beyond, Pitx2 is no longer required for their survival. The ﬁnding that
MRF expression is insufﬁcient to prevent apoptosis in TMX10 mutant
EOM precursors suggests that Pitx2 has other survival functions in
addition to MRF activation between e10.5 and e14.5. The identiﬁca-
tion of these functions, as well as the mechanism by which Pitx2
prevents cell death at the e9.5 checkpoint, is an important future
direction.Pitx2 directly activates expression of MRFs
Despite the constraints of the temporal knockout, we observe a
substantial reduction in the number of cells expressing MYF5, MYOD,
and MYOGENIN, and signiﬁcant decreases in the expression levels of
all four MRF mRNAs in e11.5 TMX10 mutant EOMs. Consistent with
this, deletion of Pitx2 in the EOMs post-natally, when it is expressed
primarily in satellite cells, results in dramatic decreases in the
expression levels of Myf5, MyoD and Myogenin (Zhou et al., 2009).
These genetic data indicate Pitx2 is an upstream activator of MRF
expression in the EOMs.
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Myf5 and MyoD, two key MRFs, demonstrates that these genes are
direct targets of PITX2. It is intriguing that PITX2 can utilize the
promoters of Myf5 and MyoD to activate their expression. A series of
complex enhancers regulate the expression ofMyoD and in particular
Myf5 in most locations of expression, including the branchial arches.
However, an EOM speciﬁc enhancer has never been described, and the
promoters are sufﬁcient to drive expression in the developing EOMs
for bothMyf5 andMyoD (Carvajal et al., 2001, 2008; Goldhamer et al.,
1992; Patapoutian et al., 1993). The exact mechanism(s) of activation
of the promoters by PITX2 remain to be determined. We hypothesize
that PITX2 functions as a typical site-speciﬁc transcription factor, but
PITX2 could also act as a chromatin-remodeling factor and enhance
transcription through epigenetic mechanisms, similar to Pax7
(McKinnell et al., 2008). This remains an important area for further
study.
Our results suggest a model for MRF activation in primary EOM
myogenesis (Fig. 7C). Sambasivan et al. recently showed Myf5 and
Mrf4 activate MyoD, which then activates Myogenin (Sambasivan et
al., 2009). We now provide genetic and biochemical evidence that
PITX2 directly activates expression of Myf5 and genetic evidence that
it acts upstream ofMrf4 as well. Our results also afﬁrmMyogenin acts
largely downstream of MyoD, as MYOGENIN is lost in mutant EOM
precursors where MYOD is also lost at e11.5. However, we showed
PITX2 directly activates expression of MyoD (Fig. 7C). Sambasivan et
al. showed a small but signiﬁcant population of cells expressingMYOD
in Myf5;Mrf4 double mutant EOM primordia, indicating that there is
an independent pathway for activatingMyoD expression (Sambasivan
et al., 2009). We propose that Pitx2 is part of this Myf5;Mrf4
independent pathway, suggesting that Pitx2 alone is sufﬁcient to
activate MyoD in a subset of EOM precursors. This is consistent with
the ability of PITX2 to activate the human MYOD promoter in CHO
cells that lack MRF expression (Fig. S6). The loss of MYOD expression
in some EOM precursor cells that express MYF5 protein (Figs. 4A–I),
and the greater reduction in MyoD mRNA expression than Myf5 or
Mrf4 (Fig. 4J), suggest that Pitx2 is also necessary to activate MyoD
expression, even ifMyf5 is present. We also found that PITX2 is able to
activate the human MYOD promoter in C2C12 muscle precursor cells
at levels three fold greater than in CHO cells (Fig. S6). This suggests
that PITX2 may have a muscle-speciﬁc co-factor that enhances
activation of the MyoD promoter. This factor could be Myf5, Mrf4, or
one of their downstream target genes such as Mef2c (17260) (Dodou
et al., 2003). Thus we propose that in wildtype EOM precursors, PITX2
works with MYF5 and MRF4 to activate MyoD. The ability of Pitx2 to
activate MRF expression distinguishes it as the primary activator of
EOM cell fate speciﬁcation, in addition to its critical role in EOM
precursor survival.
Despite the important roles we have demonstrated here for Pitx2 in
extraocularmuscle speciﬁcation, other factors are likely to be critical for
extraocular myogenesis. These include a constantly changing milieu of
extracellular signals, which may emanate from the neural tube, the
neural crest or the eye itself (Mootoosamy and Dietrich, 2002; Rinon
et al., 2007; Tzahor et al., 2003). The input of extracellular signals likely
underlieswhyPITX2 is present in EOMprimordia for several days before
myogenesis is initiated. Additionally, other transcription factors not yet
identiﬁed may also be required, or some of the myogenic transcription
factors required in the branchial arches, such as Tbx1 andMusculin, may
play supporting roles in extraocular myogenesis.
Pitx2 in the development of other muscle populations
Similar to its functions in extraocular muscle development, Pitx2 is
required for both precursor survival and cell fate speciﬁcation in the
muscles of the ﬁrst branchial arch (Dong et al., 2006; Shih et al.,
2007a). Likewise, in the pituitary gland, Pitx2 is ﬁrst required for the
survival of the precursor, Rathke's pouch, and subsequently for theactivation of lineage-speciﬁc transcription factor genes (Charles et al.,
2005; Suh et al., 2002). Although Pitx2 does not play an anti-apoptotic
role in all tissues where it is expressed, other genes that activate the
MRFs display this multifunctionality. Pax3 and Pax7 are required in
the somites for normal proliferation, survival and MRF activation
(Collins et al., 2009; Relaix et al., 2006; 2005).
Given its essential role in EOM and branchial arch myogenesis, it is
intriguing that Pitx2 is not required for myogenesis in the trunk and
limb, where it is also expressed. This may be due to redundancy in the
expression of the homologous genes Pitx1 (18740) and Pitx3 (18742)
(L'Honore et al., 2007; Lanctot et al., 1999). Double knockouts would
be necessary to uncover these functions, but mounting evidence
suggests that Pitx genes do play a role in trunk and limb myogenesis
(Abu-Elmagd et al., 2010; L'Honore et al., 2007). While Pitx2 is
expressed too late to initiate MRF expression in the somites, our
results with the C2C12 limb muscle precursor cells indicate that Pitx2
may maintain MRF expression in the somites. The functions of Pitx
genes in the speciﬁcation of the craniofacial and somite-derived
muscles may be conserved, but the temporal aspect of these functions
has changed.
Conclusions
Here we have shown that Pitx2 functions in the activation of the
muscle regulatory factorsMyf5,Mrf4,MyoD, andMyogenin. Like other
activators of myogenesis, Pitx2 plays a multi-functional role in
extraocular muscle development by regulating cell survival and cell
fate speciﬁcation. The role of Pitx2 in activatingMRF transcriptionmay
extend to myogenesis throughout the developing embryo, but
currently only in the extraocular muscles does Pitx2 operate alone
at the top of the myogenic cascade.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ydbio.2010.10.028.
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